SK bioscience Leads Gates-Funded AI Initiative to Streamline Vaccine Development Decisions — SK bioscience Co., Ltd.

Event summary

SK bioscience will lead the Gates Foundation-funded ROTOR project, an AI-powered platform for evidence-based clinical development decision-making.
The initiative involves collaboration with PATH, Slalom, and SK AX to develop a scalable AI solution applicable across various vaccines and disease areas.
The platform will be developed and validated using rotavirus vaccine development experience and datasets from both SK bioscience and PATH.
SK bioscience aims to strengthen R&D capabilities among vaccine developers in low- and middle-income countries (LMICs) and contribute to expanding global vaccine access.

The big picture

SK bioscience's AI-powered initiative addresses a critical gap in vaccine development decision-making, particularly in fields like rotavirus where validated immune correlates of protection are limited. The project aligns with broader industry trends towards digital transformation and AI-driven innovation in pharmaceutical R&D. By leveraging extensive clinical and research datasets, the platform aims to optimize clinical development strategies and facilitate more informed decisions under uncertainty.

What we're watching

Platform Scalability: The pace at which the ROTOR platform can evolve into a scalable AI solution applicable across a broad range of vaccines and disease areas.
R&D Efficiency: How the AI-powered decision-making framework will improve the efficiency of vaccine development programs, particularly in reducing uncertainty in Phase III clinical trials.
Global Health Impact: Whether the initiative can successfully strengthen R&D capabilities among vaccine developers in LMICs and contribute to expanding global vaccine access.